Blueprint Medicines Balance Sheet Health
Financial Health criteria checks 4/6
Blueprint Medicines has a total shareholder equity of $313.1M and total debt of $647.8M, which brings its debt-to-equity ratio to 206.9%. Its total assets and total liabilities are $1.2B and $886.5M respectively.
Key information
206.9%
Debt to equity ratio
US$647.78m
Debt
| Interest coverage ratio | n/a |
| Cash | US$734.17m |
| Equity | US$313.15m |
| Total liabilities | US$886.50m |
| Total assets | US$1.20b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2L9's short term assets ($854.8M) exceed its short term liabilities ($257.7M).
Long Term Liabilities: 2L9's short term assets ($854.8M) exceed its long term liabilities ($628.8M).
Debt to Equity History and Analysis
Debt Level: 2L9 has more cash than its total debt.
Reducing Debt: 2L9's debt to equity ratio has increased from 0% to 206.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2L9 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2L9 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.